5 research outputs found
[3<i>a</i>,4]-Dihydropyrazolo[1,5<i>a</i>]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors
A series of novel [3<i>a</i>,4]dihydropyrazolo[1,5<i>a</i>]pyrimidines were identified, which were highly potent
and selective inhibitors of PI3Kβ. The template afforded the
opportunity to develop novel SAR for both the hinge-binding (R<sub>3</sub>) and back-pocket (R<sub>4</sub>) substitutents. While cellular
potency was relatively modest due to high protein binding, the series
displayed low clearance in rat, mouse, and monkey
Discovery of a Potent Class of PI3Kα Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT)
In the search of PI3K p110α
wild type and H1047R mutant selective small molecule leads, an encoded
library technology (ELT) campaign against the desired target proteins
was performed which led to the discovery of a selective chemotype
for PI3K isoforms from a three-cycle DNA encoded library. An X-ray
crystal structure of a representative inhibitor from this chemotype
demonstrated a unique binding mode in the p110α protein
Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors
A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors
has been identified. This chemotype has provided an excellent tool
compound, <b>18</b>, that showed potent growth inhibition in
the PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage-independent
conditions, and it also demonstrated pharmacodynamic effects and efficacy
in a PTEN-deficient prostate cancer PC-3 xenograft mouse model
Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors
A novel series of potent and selective
hexokinase 2 (HK2) inhibitors,
2,6-disubstituted glucosamines, has been identified based on HTS hits,
exemplified by compound <b>1</b>. Inhibitor-bound crystal structures
revealed that the HK2 enzyme could adopt an “induced-fit”
conformation. The SAR study led to the identification of potent HK2
inhibitors, such as compound <b>34</b> with greater than 100-fold
selectivity over HK1. Compound <b>25</b> inhibits <i>in
situ</i> glycolysis in a UM-UC-3 bladder tumor cell line via <sup>13</sup>CNMR measurement of [3-<sup>13</sup>C]lactate produced from
[1,6-<sup>13</sup>C<sub>2</sub>]glucose added to the cell culture
Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors
A novel series of potent and selective
hexokinase 2 (HK2) inhibitors,
2,6-disubstituted glucosamines, has been identified based on HTS hits,
exemplified by compound <b>1</b>. Inhibitor-bound crystal structures
revealed that the HK2 enzyme could adopt an “induced-fit”
conformation. The SAR study led to the identification of potent HK2
inhibitors, such as compound <b>34</b> with greater than 100-fold
selectivity over HK1. Compound <b>25</b> inhibits <i>in
situ</i> glycolysis in a UM-UC-3 bladder tumor cell line via <sup>13</sup>CNMR measurement of [3-<sup>13</sup>C]lactate produced from
[1,6-<sup>13</sup>C<sub>2</sub>]glucose added to the cell culture